Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
OHSU Knight Cancer Institute
Assistance Publique - Hôpitaux de Paris
M.D. Anderson Cancer Center
Mayo Clinic
Mayo Clinic
UNICANCER
Mayo Clinic
Mayo Clinic
Fudan University
University Hospital, Montpellier
Centre Leon Berard
The Netherlands Cancer Institute